Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chim C Lang

Showing results (11-20 of 270) with videos related to

Pageof 27
Sort By:
Current Opinion in Pharmacology|May 14, 2021
Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]Graham Rena, Ify R Mordi, Chim C Lang
Cardiovascular Therapeutics|May 20, 2008
Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE StudyMaheshwar Pauriah, Allan D Struthers, Chim C Lang
Current Heart Failure Reports|November 16, 2013
Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failureArchyut Valluri, Allan D Struthers, Chim C Lang
Cardiac Failure Review|June 13, 2018
Iron Therapy in Heart Failure: Ready for Primetime?Ify R Mordi, Aaron Tee, Chim C Lang
Current Opinion in Pharmacology|December 3, 2020
Metformin: still the sweet spot for CV protection in diabetes?Graham Rena, Ify R Mordi, Chim C Lang
Diseases (Basel, Switzerland)|September 22, 2017
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart FailureAbbey Steggall, Ify R Mordi, Chim C Lang
Circulation|January 21, 2025
SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic GapIfy R Mordi, Rory J McCrimmon, Chim C Lang
Circulation|July 19, 2021
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)"Jagdeep S Singh, Allan D Struthers, Chim C Lang
European Journal of Heart Failure|October 9, 2018
What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? ReplyKoen W Streng, Chim C Lang, Adriaan A Voors
The New England Journal of Medicine|October 8, 2015
Ezetimibe plus a Statin after Acute Coronary SyndromesJagdeep S Singh, Allan D Struthers, Chim C Lang
Pageof 27

Showing results (11-20 of 270) with videos related to

Sort By:
Pageof 27
Current Opinion in Pharmacology|May 14, 2021
Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]Graham Rena, Ify R Mordi, Chim C Lang
Cardiovascular Therapeutics|May 20, 2008
Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE StudyMaheshwar Pauriah, Allan D Struthers, Chim C Lang
Current Heart Failure Reports|November 16, 2013
Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failureArchyut Valluri, Allan D Struthers, Chim C Lang
Cardiac Failure Review|June 13, 2018
Iron Therapy in Heart Failure: Ready for Primetime?Ify R Mordi, Aaron Tee, Chim C Lang
Current Opinion in Pharmacology|December 3, 2020
Metformin: still the sweet spot for CV protection in diabetes?Graham Rena, Ify R Mordi, Chim C Lang
Diseases (Basel, Switzerland)|September 22, 2017
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart FailureAbbey Steggall, Ify R Mordi, Chim C Lang
Circulation|January 21, 2025
SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic GapIfy R Mordi, Rory J McCrimmon, Chim C Lang
Circulation|July 19, 2021
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)"Jagdeep S Singh, Allan D Struthers, Chim C Lang
European Journal of Heart Failure|October 9, 2018
What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? ReplyKoen W Streng, Chim C Lang, Adriaan A Voors
The New England Journal of Medicine|October 8, 2015
Ezetimibe plus a Statin after Acute Coronary SyndromesJagdeep S Singh, Allan D Struthers, Chim C Lang
Pageof 27